NICM
ABCL icon

Neo Ivy Capital Management’s AbCellera Biologics ABCL Stock Holding History

Neo Ivy Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47,748
Closed -$308K – 309
2023
Q2 		$308K Buy
+47,748
New +$326K 0.16% 190
2022
Q4 		$235K Buy
23,178
+21,026
+977% +$243K 0.16% 213
2022
Q3 		$21K Buy
+2,152
New +$23.6K 0.06% 289

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Neo Ivy Capital Management's ABCL Position: Q3 2023 in Review

Neo Ivy Capital Management sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 47,748 shares — an estimated $308K sold.

Neo Ivy Capital Management first reported a position in ABCL in Q3 2022 and held it in 3 quarters. The position peaked at $308K in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Neo Ivy Capital Management reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Neo Ivy Capital Management sold 47,748 AbCellera Biologics shares in Q3 2023, an estimated $308K.
  • Neo Ivy Capital Management first reported a position in AbCellera Biologics in Q3 2022 and held it in 3 quarters.
  • Neo Ivy Capital Management's AbCellera Biologics position peaked at $308K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Neo Ivy Capital Management's 13F filing for Q3 2023, filed 30 Nov 2023.